(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that the U.S. Food and Drug Administration or FDA has approved its Truqap (capivasertib) in combination with Faslodex ...

AstraZeneca’s (AZ) AKT inhibitor Truqap (capivasertib) in combination with its endocrine therapy Faslodex (fulvestrant) has been approved by the US Food and Drug Administration (FDA) to treat a subset ...

The Food and Drug Administration (FDA) approved Faslodex (fulvestrant) to treat patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer in ...

Adding Truqap to Faslodex improved outcomes in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer. Patients with HR-positive, HER2-negative locally advanced or ...

The FDA approval is based on data from the Phase 3 MONARCH 2 trial, which met the study's primary endpoint of PFS. The expanded approval was supported by data from the Phase 3 MONARCH 2 trial (n=669) ...

The approval was supported by data from the Phase 3 FALCON trial (n=462) that enrolled postmenopausal women with HR+ metastatic or locally advanced breast cancer. The approval was supported by data ...

Faslodex (fulvestrant) is a prescription medicine used for people with certain types of breast cancer. Faslodex is given as an injection into the buttocks (gluteal area) by a health care provider in a ...

AstraZeneca has announced results from a phase 3 trial of its breast cancer drug candidate Faslodex (fulvestrant). The drug was found to hold back tumour growth for longer than its other cancer drug ...

AstraZeneca’s Faslodex has been cleared on both sides of the Atlantic for use in combination with a CDK4/6 inhibitor. AstraZeneca’s Faslodex has been cleared on both sides of the Atlantic for use in ...